Komori
Earnings4599StemRIM Inc.Pharmaceuticals

Summary of Interim Financial Results for the Second Quarter of the Fiscal Year Ending July 2026 [Japanese GAAP] (Non-consolidated)

Business revenue was again absent in the interim period, as in the same period of the previous year, while the operating loss narrowed from ¥1,066,080 thousand to ¥992,917 thousand, a reduction of ¥73,163 thousand. The interim net loss also narrowed. Research and development expenses increased, while selling, general and administrative expenses decreased.

Worth reading
39Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
73163
¥ thousand
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Interim period (second quarter)1 August 2025 to 31 January 2026Non-consolidated (standalone)Japanese GAAP
Operating profit-992¥ million
Ordinary income-958¥ million
Net income attributable to owners of the parent-928¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share△14.91円
Financial position at period-end
Total assets6,812¥ million
of which net assets 6,573 ¥ millionEquity ratio 74.6%vs. prior year-end -3.4pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-789,495
Investment-1,752,261
Financials0
Net change-2,541,756

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥4,452,836 thousand
Outlook and shareholder returns
Annual Dividend Forecast¥0.00 → ¥0.00
Factors Behind Changes in Business Performance

事業収益は前年同期と同じくなし。研究開発費は739,576千円から748,507千円に増加した一方、販売費及び一般管理費は326,504千円から244,410千円に減少し、営業損失は縮小した。

Disclosure regarding the going concern assumption

No applicable matters

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets -, Gain on reversal of subscription rights to shares ¥30,342 thousand / Extraordinary loss Loss on retirement of non-current assets ¥0 thousand
Depreciation and amortization¥24,500 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End62,681,200 shares
Treasury Shares at Period-End121 shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 August 2025 to 31 January 2026
Operating profit¥-992 million
Ordinary income¥-958 million
Profit attributable to owners of the parent¥-928 million
Net income per share△14.91円
Equity ratioEnd of the current fiscal period 74.6% / End of previous period 78.0%
Total assets¥6,812 million
Net assets¥6,573 million
Cash flows from operating activities¥-789,495 thousand
Cash flows from investing activities¥-1,752,261 thousand
Cash flows from financing activities¥0 thousand
Cash and cash equivalents at end of period¥4,452,836 thousand
Annual Dividend Forecast¥0.00 → ¥0.00
Depreciation and amortization¥24,500 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets -, Gain on reversal of subscription rights to shares ¥30,342 thousand / Extraordinary loss Loss on retirement of non-current assets ¥0 thousand
Disclosure regarding the going concern assumptionNo applicable matters
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End62,681,200 shares
Treasury Shares at Period-End121 shares
Factors Behind Changes in Business Performance事業収益は前年同期と同じくなし。研究開発費は739,576千円から748,507千円に増加した一方、販売費及び一般管理費は326,504千円から244,410千円に減少し、営業損失は縮小した。
Items this document does not state (13)
Net SalesOperating MarginFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

事業収益は前年同期と同じくなく、研究開発費は増加した一方、販売費及び一般管理費が減少した。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Interim Financial Results for the Second Quarter of the Fiscal Year Ending July 2026 [Japanese GAAP] (Non-consolidated) | StemRIM Inc. (4599) timely disclosure | Komori